Published in Neurobiol Dis on April 01, 1996
Measuring Levels of SMN in Blood Samples of SMA Patients | NCT00061607
Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature (2008) 12.21
Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci (2009) 4.16
Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol (2003) 2.94
Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet (2008) 2.82
Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci (2009) 2.71
Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One (2007) 2.70
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol (2005) 2.44
Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum Mol Genet (2008) 2.35
The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy. Mol Cell Biol (2005) 2.23
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet (2011) 2.13
Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis (2007) 2.10
A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol (2003) 1.75
Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet (2010) 1.75
Modeling spinal muscular atrophy in Drosophila. PLoS One (2008) 1.71
SMN is required for sensory-motor circuit function in Drosophila. Cell (2012) 1.68
Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS One (2010) 1.63
Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum Mol Genet (2011) 1.61
Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy. J Cell Biol (2007) 1.57
Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet (2009) 1.53
Coiled bodies and gems: Janus or gemini? Am J Hum Genet (1998) 1.51
Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet (2009) 1.46
Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet (2011) 1.44
Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med (2012) 1.44
Development of a single vector system that enhances trans-splicing of SMN2 transcripts. PLoS One (2008) 1.43
Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci (2012) 1.42
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol (2011) 1.32
Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J Neurosci (2010) 1.32
Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet (2006) 1.31
A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. Hum Mol Genet (2009) 1.31
Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet (2009) 1.30
Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res (2012) 1.26
Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev Biol (2011) 1.26
Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol (2012) 1.25
Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Hum Mol Genet (2011) 1.24
Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther (2014) 1.21
Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther (2014) 1.20
Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl Cell Differ (2009) 1.17
Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol (2012) 1.17
Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci U S A (2000) 1.14
Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem Biophys Res Commun (2009) 1.14
Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem Biophys Res Commun (2009) 1.12
Building robust transcriptomes with master splicing factors. Cell (2014) 1.12
The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet (2013) 1.09
Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev (2015) 1.09
Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol Ther (2011) 1.07
Conserved genes act as modifiers of invertebrate SMN loss of function defects. PLoS Genet (2010) 1.07
Specific sequence features, recognized by the SMN complex, identify snRNAs and determine their fate as snRNPs. Mol Cell Biol (2005) 1.07
Proteomic assessment of a cell model of spinal muscular atrophy. BMC Neurosci (2011) 1.05
Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia (2013) 1.05
Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med (2012) 1.05
Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology (2007) 1.04
Identification of a novel cyclic AMP-response element (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron (SMN) gene. J Biol Chem (2004) 1.03
Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy. Biochem Biophys Res Commun (2011) 1.01
A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy. J Neurosci Methods (2006) 1.00
A cell-autonomous defect in skeletal muscle satellite cells expressing low levels of survival of motor neuron protein. Dev Biol (2012) 1.00
A novel cell immunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol (2006) 1.00
The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy. Hum Mol Genet (2012) 0.98
SMN requirement for synaptic vesicle, active zone and microtubule postnatal organization in motor nerve terminals. PLoS One (2011) 0.97
Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans. Neurobiol Dis (2010) 0.97
A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein. Neurosci Lett (2008) 0.97
Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. Eur J Hum Genet (2012) 0.96
Deficiency of the zinc finger protein ZPR1 causes neurodegeneration. Proc Natl Acad Sci U S A (2006) 0.96
Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum Gene Ther (2013) 0.95
Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One (2012) 0.95
Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum Mol Genet (2014) 0.94
Lymphotropic Herpesvirus saimiri uses the SMN complex to assemble Sm cores on its small RNAs. Mol Cell Biol (2005) 0.94
Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy. Muscle Nerve (2011) 0.94
Heterogeneity of subcellular localization and electrophoretic mobility of survival motor neuron (SMN) protein in mammalian neural cells and tissues. Proc Natl Acad Sci U S A (1998) 0.92
Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci (2015) 0.92
Spinal muscular atrophy disease: a literature review for therapeutic strategies. J Med Life (2010) 0.92
Stem cell transplantation for motor neuron disease: current approaches and future perspectives. Neurotherapeutics (2011) 0.92
Discovery, synthesis, and biological evaluation of novel SMN protein modulators. J Med Chem (2011) 0.91
Spliceosomal small nuclear ribonucleoprotein biogenesis defects and motor neuron selectivity in spinal muscular atrophy. Brain Res (2012) 0.91
Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy. J Mol Cell Cardiol (2012) 0.91
Reduced levels of survival motor neuron protein leads to aberrant motoneuron growth in a Xenopus model of muscular atrophy. Neurogenetics (2009) 0.91
A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol (2015) 0.90
SMN deficiency reduces cellular ability to form stress granules, sensitizing cells to stress. Cell Mol Neurobiol (2011) 0.90
Survival motor neuron protein regulates stem cell division, proliferation, and differentiation in Drosophila. PLoS Genet (2011) 0.89
SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMNΔ7 mouse model of SMA. Hum Mol Genet (2015) 0.89
Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB/N mice. Neurobiol Dis (2011) 0.89
Therapy development in spinal muscular atrophy. Nat Neurosci (2010) 0.88
Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy. J Neurosci Methods (2008) 0.87
Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics (2014) 0.87
Therapeutic developments in spinal muscular atrophy. Ther Adv Neurol Disord (2010) 0.87
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience. J Child Neurol (2016) 0.87
Solution structure of the core SMN-Gemin2 complex. Biochem J (2012) 0.86
The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics (2015) 0.86
Transcriptome profiling of spinal muscular atrophy motor neurons derived from mouse embryonic stem cells. PLoS One (2014) 0.86
Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. J Biomol Screen (2012) 0.86
The survival motor neuron protein forms soluble glycine zipper oligomers. Structure (2012) 0.85
A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids (2014) 0.84
Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol (2015) 0.84
Skeletal muscle DNA damage precedes spinal motor neuron DNA damage in a mouse model of Spinal Muscular Atrophy (SMA). PLoS One (2014) 0.84
Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. PLoS One (2011) 0.84
Tetanus toxin C-fragment: the courier and the cure? Toxins (Basel) (2010) 0.84
Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics. Arch Med Sci (2011) 0.84
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol Med (2013) 0.84
Deficiency of the Survival of Motor Neuron Protein Impairs mRNA Localization and Local Translation in the Growth Cone of Motor Neurons. J Neurosci (2016) 0.83
Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron (1996) 7.20
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron (1995) 6.03
Neuropathology of cervical dystonia. Exp Neurol (2012) 1.69
Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia. Neurology (2004) 1.66
Associations between retinal nerve fiber layer abnormalities and optic nerve examination. Neurology (2010) 1.49
Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology (2006) 1.45
Ventral root avulsion: an experimental model of death of adult motor neurons. J Comp Neurol (1994) 1.32
Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol (1994) 1.22
Axonal transport of mutant superoxide dismutase 1 and focal axonal abnormalities in the proximal axons of transgenic mice. Neurobiol Dis (1998) 1.16
TNF-alpha mediates SDF-1 alpha-induced NF-kappa B activation and cytotoxic effects in primary astrocytes. J Clin Invest (2001) 1.09
Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am J Pathol (1994) 1.05
Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism. J Pharmacol Exp Ther (2007) 1.05
Rapid anterograde axonal transport of the cellular prion glycoprotein in the peripheral and central nervous systems. J Biol Chem (1994) 1.01
Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol (2000) 0.99
Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol (1995) 0.90
Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). Neuropathol Appl Neurobiol (2003) 0.90
Human immunodeficiency virus and the peripheral nervous system workshop. Arch Neurol (2001) 0.89
Irreversible regional cerebral ischemia: serial MR imaging and proton MR spectroscopy in a nonhuman primate model. AJNR Am J Neuroradiol (1993) 0.87
Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis. J Rheumatol (1995) 0.86
HIV in the brain: RNA levels and patterns of zidovudine resistance. Neurology (2001) 0.82
Biocompatibility of fixation materials in the brain. Plast Reconstr Surg (1997) 0.80
Histologic abnormalities associated with gadolinium enhancement on MR in the initial hours of experimental cerebral infarction. AJNR Am J Neuroradiol (1994) 0.77
Amyotrophic lateral sclerosis and Alzheimer disease. Lessons from model systems. Rev Neurol (Paris) (1997) 0.77
Neurodegenerative diseases and model systems. Cold Spring Harb Symp Quant Biol (1996) 0.77
Familial amyotrophic lateral sclerosis and Alzheimer's disease. Transgenic models. Adv Exp Med Biol (1998) 0.75
The need for caution in considering the diagnostic utility of antibasal ganglia antibodies in movement disorders. Arch Dis Child (2004) 0.75
Congenital myotonic dystrophy in tropical countries. J Neurol Sci (1993) 0.75
Motor neuron disease and model systems: aetiologies, mechanisms and therapies. Ciba Found Symp (1996) 0.75
Thymic hyperplasia in a patient with recurrent transverse myelitis with clinical resolution after thymectomy. J Neurol Neurosurg Psychiatry (2008) 0.75